Supporting the Biggest Brands in Advanced Therapies

We empower leading brands to elevate their visibility and engagement, turning potential leads into devoted customers and champions throughout their commercial journey. As a comprehensive content marketing ally for the advanced therapies market, we offer strategic insights, expert consultation, tailored content creation, and wide distribution. Our commitment to educating the advanced therapies community has ingrained in us the power of impactful content. Today, we pave the way for the foremost brands in advanced therapies to share their narratives and forge trusted bonds through content.

Your content marketing agency for Advanced Therapies

Past Webinars

Podcast

Intensified extracellular vesicle production in fixed-bed bioreactors: Discover low-footprint, automated solutions for low-cost extracellular vesicles manufacturing

Are you looking for a cost-effective, high-productivity extracellular vesicle (EV) production platform that overcomes traditional manufacturing challenges? Join us to discover how Univercells Technologies’ scalable fixed-bed design is transforming EV manufacturing.
08:00 [PDT] | 16:00 [BST]
Podcast

Maximizing cost efficiency, reducing GMP footprint, and eliminating bottlenecks in Lentiviral virus production: A Case Study with the Cytegrity™ Producer Cell Line in the scale-X™ Fixed-Bed Bioreactor.

Discover revolutionary advancements in LVV production with our expert-led webinar, addressing industry challenges such as batch variability and high process costs. Learn how the Cytegrity™ Producer Cell Line system and Univercells Technologies’ scale-X™ bioreactor can transform your manufacturing processes.
Watch On Demand
Podcast

Going Non-Viral: How Cell Therapy Manufacturing is Moving Away From Viral Vectors

Are you interested in editing cells using a CRISPR-based non-viral vector capable of achieving knock-in rates of 70–90%? Don’t miss this webinar discussing this approach and the specific strategies to improve manufacturing timelines and costs.
Watch On Demand
Our eBooks
The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
Advanced therapies’ market access is a hot topic. Joining Phacilitate to shed some light on market access struggles are Director at NJ Redfern Limited and ex-bluebird bio UK GM Nicola Redfern, former SVP & CBO at Novartis Gene Therapies and current AviadoBio CEO Lisa Deschamps, and, Vice President and Global Head of Value and Access, at Novartis, Tay Salimullah.
What’s preventing developers from designing mechanistically relevant assays? This report examines this question, focusing on the identification and measurement of appropriate CQAs, the value of fit-for-purpose analytics technologies and what the future of CGT manufacturing analytics should look like.
Exploring digital solutions for cell and gene therapy manufacturing: a Pharma 4.0 perspective.